Case reports suggest that medical treatment with GnRH agonists are a viable option for both primary and recurrent tumors, especially given the radical and often debilitating nature of the surgery required to remove the tumor. Further evidence is required to establish the true value of this treatment. 1. Martínez AA, Hernández-González M, Carrera González E. Angiomixoma agresivo en hombres. Rev Med Hosp Gen Mex 2007; 702: 78-81. 2. Jingping Z, Chunfu Z. Clinical Experiences on Aggressive Angiomyxoma in China Report of 93 Cases. Int J Gynecol Cancer 2010; 20: 303-307. 3. Adwan H, Patel B, Kamel D, Glazer G. A solitary encapsulated pelvic aggressive angiomyxoma. Ann R Coll Surg Engl 2004; 86: W1-3. 4. Camps Lasa J, Navarro Luna A, Muñoz Duyos A, García Domingo M, Molina CM. Angiomixoma agresivo pelviperineal en el varón. Cir Esp 2008; 842: 101-11. 5. Hastak MS, Raghuvanshi SR, Sahu S, Vyankatesh A, Ramraje SN, Ranjan A. Aggressive Angiomyxoma in men. JAPI 2008; 56: 373-5. 6. Boren T, Lapolla J, Martino M, Nirgudkar P. Aggressive Angiomyxoma: A Case of Multiple Recurrences and Review of the Literature. Journal of Pelvic Medicine & Surgery 2006; 12: 151-6. 7. Mera Velasco S, Cabello Burgos AJ, Ruiz López M, González Poveday I, Santoyo Santoyo J. Resección laparoscópica de angiomixoma pélvico agresivo. CIR ESP. 2010; 882: 119-132. 8. Giles DL, Liu PT, Lidner TK, Magtibay PM. Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection. International Journal of Gynecological Cancer 2007; 8: 369-385. 9. Outwater EK, Marchetto BE, Wagner BJ, Siegelman ES. Aggressive Angiomyxoma: Findings on CT and MR imaging. AJR 1999; 172: 435-438. 10. Xambre L, Cerqueira M, Guimarães I. Angiomixoma agresivo penoescrotal. Actas Urológicas Españolas 2009; 333: 321-326. 14. Morag R, Fridman E, Mor Y. Aggressive Angiomyxoma of the Scrotum Mimicking Huge Hydrocele: Case Report and Literature Review. Case Reports in Medicine. 2009. p. 1-3. 15. Andres LA, Mishra MJ. Angiomyxoma diagnosed in a man presenting for abdominal lipectomy. Can J Plast Surg 2007; 15: 163-164. 16. Poirier M, Fraser R, Meterissian S. Unusual Abdominal and Pelvic Tumors. Journal of Clinical Oncology 2003; 21: 3535-3541. 17. Rawlinson NJ, West WW, Nelson M, Bridge JA. Aggressive Angiomyxoma with t12;21 and HMGA2 Rearrangement: Report of a Case and Review of the Literature. Cancer Genet Cytogenet 2008; 1812: 119-124. 18. Rabban JT, Dal Cin P, Oliva E. HMGA2 Rearrangement in a case of vulvar Aggressive Angiomyxoma. Int J Gynecol Pathol 2006; 254: 403-407. 19. McCluggage WG, Connolly L, McBride HA. HMGA2 is a Sensitive but Not Specific Immunohistochemical Marker of Vulvovaginal Aggressive Angiomyxoma. Am J Surg Pathol 2010; 347: 1037-1042.
Los reportes de casos que sugieren que el tratamiento médico con agonistas de la GnRH son una opción viable tanto para los tumores primarios como para los recurrentes, especialmente dada la naturaleza radical y frecuentemente debilitante de la cirugía requerida para extraer el tumor; se requiere de mayor evidencia para poder establecer su verdadera utilidad.